COMP <GO>
ALNY vs UNH // REVENUE GROWTH (YOY)
Alnylam Pharmaceuticals Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: ALNY 7
— UNH 8
▲ REVENUE GROWTH (YOY) LEADER: ALNY
LAST: $165.00 (-5.17%) • MKT CAP: $23.28B
revenue-growth
65.20%
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
revenue-growth
6.46%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ALNY VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ALNY | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 81.80% | 88.57% | -6.77 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 21.30% | 11.47% | +9.83 | ALNY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 42.4x | 16.4x | +25.95 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 2.00% | 6.48% | -4.48 | UNH | /fcf-yield <GO> |
| Operating Margin | 13.50% | 4.82% | +8.68 | ALNY | /operating-margins <GO> |
| Net Profit Margin | 8.40% | 3.14% | +5.26 | ALNY | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 65.20% | 6.46% | +58.74 | ALNY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.16 | 3.12 | +0.04 | ALNY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | ALNY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.74% | +0.16 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 22.1 | 56.0 | -34.00 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 0.33 | +0.67 | ALNY | /macro-sensitivity <GO> |
| Forward P/E Multiple | 62.3x | 17.1x | +45.21 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $23.28B | $364.66B | -$341.38B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ALNY REV | UNH REV | ALNY GROSS % | UNH GROSS % | ALNY FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.71B | $447.57B | 81.8% | 88.7% | $465.4M | $16.07B |
| FY 2024 | $2.25B | $400.28B | 86.4% | 88.3% | -$42.6M | $20.70B |
| FY 2023 | $1.83B | $371.62B | 44.0% | 89.6% | $21.9M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ALNY // BETA 1.00
UNH // BETA 0.33